Physician profile
Mark R Key
NPI 1861684441
$1,922.96
in general payments reported to CMS, 2019-2025
31 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $371 · 2021: $382 · 2022: $303 · 2023: $406 · 2024: $157 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.62 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $481.92 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $226.30 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $208.21 | 2021-2024 | |
| Astellas Pharma US INC | $144.23 | 2020-2023 | Veozah |
| Mylan Specialty L.P. | $132.64 | 2021-2023 | Yupelri |
| Aimmune Therapeutics, INC. | $120.18 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals Lp | $88.36 | 2020-2023 | Breztri |
| Radius Health, INC. | $62.42 | 2019-2024 | Tymlos |
| Novo Nordisk INC | $51.58 | 2020-2025 | |
| Nabriva Therapeutics, Plc | $42.44 | 2021 | |
| Pfizer INC. | $33.09 | 2021-2023 | |
| Genentech USA, INC. | $29.39 | 2020-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $24.30 | 2025 | Lumryz |
| Otsuka America Pharmaceutical, INC. | $21.98 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $21.29 | 2024 | Daybue |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.12 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.72 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.69 | 2024 | |
| Allergan, INC. | $18.31 | 2020 | |
| Abbvie INC. | $17.96 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.27 | 2025 | Voquezna |
| Abbott Laboratories | $17.15 | 2023 | Proclaim |
| Paratek Pharmaceuticals, INC. | $14.72 | 2024 | Nuzyra |
| Sanofi Pasteur INC. | $14.52 | 2022 | |
| Amgen INC. | $13.89 | 2019 | |
| Amarin Pharma, INC. | $13.60 | 2022 | |
| Melinta Therapeutics, LLC | $13.00 | 2019 | |
| Biodelivery Sciences International, INC. | $12.99 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.97 | 2019 | |
| Aytu Biopharma, INC. | $10.93 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Key listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.